News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

General Shareholders’ Meeting 2013

Dear Shareholders,

We invite you to attend the Annual General Shareholders’ Meeting of Epigenomics AG on Monday, May 6, 2013 at 11:00 a.m., in the premises of Deutsche Bank AG , Friedrichsaal, Unter den Linden 13–15 (entrance Charlottenstraße), 10117 Berlin.

 

Invitation to the Annual General Shareholders’ Meeting 2013 of Epigenomics AG PDF
Report of the Executive Board on agenda items 5 and 6 PDF
Report of the Executive Board on agenda item 7 PDF
Annual Report 2012 (incl. Consolidated Financial Statements, Group Management Report, Supervisory Board Report, Key features of the internal control and risk management system and Remuneration Report) PDF
Financial Statements 2012 (German HGB) incl. Key features of the internal control and risk management system (German version) PDF
Explanatory Report by the Management Board on Disclosures Pursuant to Section 289 (4), Section 315 (4) HGB (German version) PDF
Explanatory Report by the Management Board on Key Features of the Internal Control and Risk Management System Related to the Group Accounting Procedures of the Company Pursuant to Section 289 (5), Section 315 (2) HGB (German version) PDF

 

 

Corporate Governance/Declaration of Governance

 2012
Declaration of Compliance with the German Corporate Governance Code pursuant to Section 161 of the German Stock Corporation Act (AktG) PDF
Declaration of Governance and reporting on Corporate Governance pursuant to Section 289a German Commercial Code (HGB) PDF

 

 

Further information

Explanation of Shareholders’ rights PDF
Articles of Association PDF
Form for the transfer of voting rights (German version) PDF

 

 

Review

Epigenomics AG held its 9th Annual General Shareholders’ Meeting in Berlin with about 60 shareholders, its representatives and guests on May 6, 2013. The presence before the voting was at 3.069.801 individual shares, equivalent to 25.65% of the authorized capital.

All TOPs were agreed to. More detailed information are available on our German website.



Archive